The Hepatorenal Syndrome Treatment Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Hepatorenal Syndrome Treatment Market:
https://www.thebusinessresearchcompany.com/report/hepatorenal-syndrome-treatment-global-market-report
According to The Business Research Company’s Hepatorenal Syndrome Treatment Global Market Report 2024, The hepatorenal syndrome treatment market size has grown strongly in recent years. It will grow from $13.85 billion in 2023 to $14.67 billion in 2024 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to automotive industry growth, aerospace sector requirements, advantages in material utilization, improved mechanical properties, stringent industry standards, efficiency and precision gains..
The hepatorenal syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $18.56 billion in 2028 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rise in renewable energy projects, growing demand for high-performance alloys, focus on sustainable manufacturing, expansion of oil and gas exploration, demand for high-performance components.. Major trends in the forecast period include integration of industry 4.0 technologies, research and development in forging techniques, customization for specific applications, automation in forging processes, innovations in heating and cooling technologies..
An increase in the incidences of patients with liver damage or cirrhosis is expected to propel the growth of the hepatorenal syndrome treatment market going forward. Cirrhosis is a severe form of liver disease in which scar tissue permanently replaces good liver tissue. Hepatorenal syndrome treatment aims to retain the patient’s kidney function while alleviating symptoms and adverse effects of the disorder. These strategies may help to improve overall health and make you a better candidate for liver transplant surgery. For instance, in September 2022, according to a Fact Sheet published by the Centers for Disease Control and Prevention, a US-based Government agency, the number of adults with diagnosed liver disease in the US was 4.5 million. Moreover, according to Medscape, a website providing access to medical information, states ALD-related fatalities increased by 17.6% between 2019 and 2021, whereas NAFLD-related deaths climbed by 14.5%. Therefore, the increase in the incidences of patients with liver damage or cirrhosis is driving the growth of the hepatorenal syndrome treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=10414&type=smp
The hepatorenal syndrome treatment market covered in this report is segmented –
1) By Type: Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome
2) By Treatment: Therapeutics, Surgical Treatment
3) By End-User: Hospitals And Clinics, Ambulatory Surgical Centers, Academic And Research Institutes, Other End-Users
Increasing research and development activities for hepatorenal syndrome treatment is a key trend gaining popularity in the hepatorenal syndrome treatment market. Companies operating in the hepatorenal syndrome treatment market are now focusing more on research and development to sustain their position in the market. For instance, in September 2022, Mallinckrodt Pharmaceuticals, an Ireland-based company specializing in developing, manufacturing, and distributing specialty products and therapies, announced the FDA approval for Terlivaz for an injection that helps adults with hepatorenal syndrome’s kidney function. The Phase 3 CONFIRM trial, the largest-ever prospective research (n=300) done to evaluate the safety and efficacy of terlipressin in patients with HRS type 1 (HRS-1) in the U.S. and Canada, was a significant factor in the FDA’s approval. Verified HRS Reversal, measured as an improvement in renal function, avoiding the need for dialysis, and short-term survival, was achieved by the CONFIRM trial’s primary endpoint (p=0.012).
The hepatorenal syndrome treatment market report table of contents includes:
1. Executive Summary
2. Hepatorenal Syndrome Treatment Market Characteristics
3. Hepatorenal Syndrome Treatment Market Trends And Strategies
4. Hepatorenal Syndrome Treatment Market – Macro Economic Scenario
5. Global Hepatorenal Syndrome Treatment Market Size and Growth
….
31. Global Hepatorenal Syndrome Treatment Market Competitive Benchmarking
32. Global Hepatorenal Syndrome Treatment Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Hepatorenal Syndrome Treatment Market
34. Hepatorenal Syndrome Treatment Market Future Outlook and Potential Analysis
35. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
